Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(7): 428-432
DOI: 10.1055/s-2007-971067
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Plasma Apelin is Lower in Patients with Elevated LDL-Cholesterol

I. Tasci 1 , T. Dogru 1 , I. Naharci 1 , G. Erdem 1 , M. I. Yilmaz 2 , A. Sonmez 1 , N. Bingol 3 , S. Kilic 4 , S. Bingol 5 , S. Erikci 1
  • 1Department of Internal Medicine, Gulhane School of Medicine, Etlik, Ankara, Turkey
  • 2Department of Nephrology, Gulhane School of Medicine, Etlik, Ankara, Turkey
  • 3Biochemistry Laboratory, Bayindir Hospital, Sogutozu, Ankara, Turkey
  • 4Department of Epidemiology, Gulhane School of Medicine, Etlik, Ankara, Turkey
  • 5Division of Biochemistry, Numune Hospital, Sihhiye, Ankara, Turkey
Further Information

Publication History

received 02.11.2006 first decision 10.01.2007

accepted 08.02.2007

Publication Date:
23 July 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Hypercholesterolemia is a major risk factor for atherosclerosis. Dysregulation of adipokines contribute to atherosclerotic diseases. Apelin has recently been shown to be secreted by the adipose tissue in association with hyperinsulinemia and inflammation. We searched plasma apelin levels in patients with elevated low density lipoprotein (LDL)-cholesterol having no additional disorder. Thirty-three patients with hypercholesterolemia and 50 age-, sex-, and body mass index-matched healthy controls were evaluated for their apelin, adiponectin and high sensitivity C-reactive protein (hsCRP) levels, and homeostasis model assessment (HOMA) indexes. Plasma apelin-12 and adiponectin were determined by ELISA and RIA, respectively. Plasma apelin levels were lower in patients with elevated LDL-cholesterol compared to healthy controls (p<0.001). Plasma adiponectin concentration was also lower in the dyslipidemic patients (p<0.001). hsCRP levels were similar in the two groups. Fasting plasma glucose was normal in both groups. HOMA indexes in the dyslipidemic group were higher than the controls (p=0.005). A mild to moderate negative correlation with HOMA and positive correlation with high density lipoprotein cholesterol of apelin was found in the dyslipidemic group. Plasma apelin is decreased in non-obese, non-diabetic and normotensive patients with elevated LDL-cholesterol. Low apelin levels in hypercholesterolemia seem associated with insulin resistance, which needs to be investigated in larger populations as well as in other atherosclerotic conditions.

Key words

Apelin - hypercholesterolemia - dyslipidemia - low density lipoprotein (LDL)-cholesterol - adiponectin - insulin resistance - homeostasis model assessment (HOMA) - high sensitivity C-reactive protein (hsCRP)

References

  • 1 Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.  Exp Clin Endocrinol Diabetes. 2005;  113 534-537
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpene C, Audigier Y, Saulnier-Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity.  Endocrinology. 2005;  146 1764-1771
    CrossrefPubMedGoogle Scholar
  • 3 Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats.  Eur J Pharmacol. 2003;  470 171-175
    CrossrefPubMedGoogle Scholar
  • 4 Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache JS, Valet P, Castan-Laurell I. TNFalpha up-regulates apelin expression in human and mouse adipose tissue.  FASEB J. 2006;  20 1528-1530
    CrossrefPubMedGoogle Scholar
  • 5 Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.  Diabetes Res Clin Pract. 2007;;  76 24-29
    CrossrefPubMedGoogle Scholar
  • 6 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 7 Ferroni P, Novo S, Davi V, Novo G, Basili S, Davi G. Circulating transforming growth factor-beta1 levels in asymptomatic carotid plaques.  Stroke. 2005;  36 525-526
    PubMedGoogle Scholar
  • 8 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
    CrossrefPubMedGoogle Scholar
  • 9 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.  N Engl J Med. 2005;  352 1685-1695
    CrossrefPubMedGoogle Scholar
  • 10 Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, Akerman K, Herzig KH. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding.  Regul Pept. 2005;  130 7-13
    CrossrefPubMedGoogle Scholar
  • 11 Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance.  Exp Clin Endocrinol Diabetes. 1999;  107 119-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.  Arterioscler Thromb Vasc Biol. 2000;  20 1595-1599
    CrossrefPubMedGoogle Scholar
  • 13 Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells.  Biochem Biophys Res Commun. 2004;  325 395-400
    CrossrefPubMedGoogle Scholar
  • 14 Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.  Regul Pept. 2004;  118 119-125
    CrossrefPubMedGoogle Scholar
  • 15 Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity.  Exp Clin Endocrinol Diabetes. 2001;  109 S189-201
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Lebovitz HE. Insulin resistance: definition and consequences.  Exp Clin Endocrinol Diabetes. 2001;  109 S135-148
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor.  J Neurochem. 2000;  74 34-41
    CrossrefPubMedGoogle Scholar
  • 18 Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action.  Endocrinology. 2005;  146 231-236
    PubMedGoogle Scholar
  • 19 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.  Exp Clin Endocrinol Diabetes. 2006;  114 127-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis.  Exp Clin Endocrinol Diabetes. 2004;  112 378-382
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 23 O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.  Gene. 1993;  136 355-360
    CrossrefPubMedGoogle Scholar
  • 24 Parhofer KG. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.  Exp Clin Endocrinol Diabetes. 2005;  113 414-417
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.  Metabolism. 2006;  55 1551-1557
    CrossrefPubMedGoogle Scholar
  • 26 Piatti P, Mario C Di, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting.  Circulation. 2003;  108 2074-2081
    CrossrefPubMedGoogle Scholar
  • 27 Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men.  JAMA. 2004;  291 1730-1737
    CrossrefPubMedGoogle Scholar
  • 28 Prabhakaran D, Anand SS. The metabolic syndrome: an emerging risk state for cardiovascular disease.  Vasc Med. 2004;  9 55-68
    CrossrefPubMedGoogle Scholar
  • 29 Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences.  Expert Rev Cardiovasc Ther. 2005;  3 465-471
    CrossrefPubMedGoogle Scholar
  • 30 Shin MJ, Lee JH, Jang Y, Park E, Oh J, Chung JH, Chung N. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant.  Metabolism. 2006;  55 918-922
    CrossrefPubMedGoogle Scholar
  • 31 Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, Naharci I, Bingol N, Kilic S, Demirtas A, Bingol S, Ozgurtas T, Erikci S. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia.  Clin Endocrinol (Oxf). 2006;  64 567-572
    CrossrefPubMedGoogle Scholar
  • 32 Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice.  Regul Pept. 2005;  131 12-17
    CrossrefPubMedGoogle Scholar
  • 33 Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.  JAMA. 2000;  284 311-318
    CrossrefPubMedGoogle Scholar
  • 34 Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.  Circ Res. 2002;  91 434-440
    CrossrefPubMedGoogle Scholar
  • 35 Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, Ghatei M, Bloom S. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats.  Biochem Biophys Res Commun. 2002;  291 1208-1212
    CrossrefPubMedGoogle Scholar
  • 36 Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.  Biochem Biophys Res Commun. 1998;  251 471-476
    CrossrefPubMedGoogle Scholar
  • 37 Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism.  Regul Pept. 2001;  99 87-92
    CrossrefPubMedGoogle Scholar
  • 38 Eynatten M von, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease.  Clin Chem. 2006;  52 853-859
    CrossrefPubMedGoogle Scholar
  • 39 Wallace AM, MacMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).  Circulation. 2001;  104 3052-3056
    CrossrefPubMedGoogle Scholar
  • 40 Weissberg P. Mechanisms modifying atherosclerotic disease - from lipids to vascular biology.  Atherosclerosis. 1999;  147 S3-10
    CrossrefPubMedGoogle Scholar
  • 41 Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Kir T, Acikel C, Bingol N, Oguz Y, Ikizler TA, Vural A. Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients.  Clin Nephrol. 2005;  64 12-19
    PubMedGoogle Scholar
  • 42 Yilmaz MI, Sonmez A, Kilic S, Celik T, Bingol N, Pinar M, Mumcuoglu T, Ozata M. The association of plasma adiponectin levels with hypertensive retinopathy.  Eur J Endocrinol. 2005;  152 233-240
    CrossrefPubMedGoogle Scholar

Correspondence

Prof. I. Tasci

GATA Ic Hastaliklari B.D.

Etlik 06018

Ankara

Turkiye

Phone: +90/31/23/04 40 18

Fax: +90/31/23/04 40 00

Email: itasci@gata.edu.tr

      >